Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
13 mai 2022 06h00 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
01 févr. 2022 09h15 HE | Qualigen Therapeutics, Inc.
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
Qualigen-Logo-Tag.png
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
18 janv. 2022 09h15 HE | Qualigen Therapeutics, Inc.
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
01 déc. 2021 15h25 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...
Qualigen-Logo-Tag.png
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
29 nov. 2021 15h50 HE | Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,...
Qualigen-Logo-Tag.png
Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results
15 nov. 2021 09h00 HE | Qualigen Therapeutics, Inc.
Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million,...